The pendulum appears to be swinging towards vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) with immune checkpoint inhibitors (ICIs) for the front-line treatment of metastatic renal cell carcinoma (mRCC).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile